## Scott T Avecilla

## List of Publications by Citations

Source: https://exaly.com/author-pdf/7497641/scott-t-avecilla-publications-by-citations.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

51 2,213 13 47 g-index

61 2,417 5.7 3.99 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
51	Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. <i>Nature Medicine</i> , <b>2004</b> , 10, 64-71	50.5	631
50	Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. <i>Nature Medicine</i> , <b>2006</b> , 12, 557-67	50.5	567
49	The bone marrow vascular niche: home of HSC differentiation and mobilization. <i>Physiology</i> , <b>2005</b> , 20, 349-56	9.8	348
48	Angiogenic factors reconstitute hematopoiesis by recruiting stem cells from bone marrow microenvironment. <i>Annals of the New York Academy of Sciences</i> , <b>2003</b> , 996, 49-60	6.5	117
47	Tie2 activation contributes to hemangiogenic regeneration after myelosuppression. <i>Blood</i> , <b>2005</b> , 106, 505-13	2.2	95
46	Thrombospondins deployed by thrombopoietic cells determine angiogenic switch and extent of revascularization. <i>Journal of Clinical Investigation</i> , <b>2006</b> , 116, 3277-91	15.9	83
45	Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy. <i>American Journal of Clinical Pathology</i> , <b>2012</b> , 137, 572-4	1.9	73
44	Functional heterogeneity of the bone marrow vascular niche. <i>Annals of the New York Academy of Sciences</i> , <b>2009</b> , 1176, 47-54	6.5	53
43	Tumor vasculature address book: identification of stage-specific tumor vessel zip codes by phage display. <i>Cancer Cell</i> , <b>2003</b> , 4, 331-3	24.3	44
42	Results of lookback for Chagas disease since the inception of donor screening at New York Blood Center. <i>Transfusion</i> , <b>2013</b> , 53, 1083-7	2.9	26
41	Ex Vivo CD34-Selected T Cell-Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host Disease and High Treatment	4.7	25
40	Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/refractory B cell non-Hodgkin lymphoma. <i>Leukemia</i> , <b>2019</b> , 33, 2540-2544	10.7	20
39	How do I perform hematopoietic progenitor cell selection?. <i>Transfusion</i> , <b>2016</b> , 56, 1008-12	2.9	16
38	Impact of Toxicity on Survival for Older Adult Patients after CD34 Selected Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 142-1	<b>49</b> 7	13
37	A novel hematopoietic progenitor cell mobilization and collection algorithm based on preemptive CD34 enumeration. <i>Transfusion</i> , <b>2015</b> , 55, 2010-6	2.9	13
36	Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34 Selected Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 1526-1535	4.7	10
35	The Impact of Toxicities on First-Year Outcomes after Ex Vivo CD34-Selected Allogeneic Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 2004-2011	4.7	9

## (2019-2016)

34	Comparison of manual hematocrit determinations versus automated methods for hematopoietic progenitor cell apheresis products. <i>Transfusion</i> , <b>2016</b> , 56, 528-32	2.9	9	
33	Effects of Late Toxicities on Outcomes in Long-Term Survivors of Ex-Vivo CD34-Selected Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 133-141	4.7	8	
32	High progression-free survival after intermediate intensity double unit cord blood transplantation in adults. <i>Blood Advances</i> , <b>2020</b> , 4, 6064-6076	7.8	7	
31	Evaluation of peripheral blood mononuclear cell collection by leukapheresis. <i>Transfusion</i> , <b>2019</b> , 59, 17	65 <u>2</u> 1377	2 6	
30	Investigational use of PEGylated carboxyhemoglobin bovine in a Jehovah' Witness with hemorrhagic shock. <i>Transfusion</i> , <b>2018</b> , 58, 2297-2300	2.9	6	
29	Can the interval between antibody identifications be increased for alloimmunized patients?. <i>Transfusion</i> , <b>2016</b> , 56, 334-8	2.9	4	
28	Severe delayed hemolytic transfusion reaction due to anti-Fy3 in a patient with sickle cell disease undergoing red cell exchange prior to hematopoietic progenitor cell collection for gene therapy. <i>Haematologica</i> , <b>2021</b> , 106, 310-312	6.6	4	
27	Immune Cytopenias after Ex Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 1136-1141	4.7	4	
26	Management of thymoma-associated pure red cell aplasia: A novel use of blood substitute HBOC-201 in a Jehovah's Witness. <i>Clinical Case Reports (discontinued)</i> , <b>2020</b> , 8, 289-292	0.7	3	
25	Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1394-1401	4.7	3	
24	Getting blood out of a stone: Identification and management of patients with poor hematopoietic cell mobilization. <i>Blood Reviews</i> , <b>2021</b> , 47, 100771	11.1	3	
23	Guidelines for Cord Blood Unit Thaw and Infusion. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1780-1783	4.7	2	
22	Engraftment kinetics after transplantation of double unit cord blood grafts combined with haplo-identical CD34+ cells without antithymocyte globulin. <i>Leukemia</i> , <b>2021</b> , 35, 850-862	10.7	2	
21	A novel method for the laboratory workup of anaphylactic transfusion reactions in haptoglobin-deficient patients. <i>Transfusion</i> , <b>2020</b> , 60, 682-687	2.9	1	
20	Method comparison study of peripheral blood CD34+ count performed on an Abbott CELL-DYN Sapphire hematology analyzer versus flow cytometry reference procedure (modified ISHAGE). <i>Advances in Cell and Gene Therapy</i> , <b>2018</b> , 1, e15	1.2	1	
19	Coagulation Factor Products <b>2019</b> , 251-260		1	
18	Transfusion Management of Patients Receiving Antithrombotic Therapy <b>2019</b> , 343-349		1	
17	Laboratory Monitoring for Heparins, Fondaparinux, Direct Thrombin Inhibitors, and Oral Anti-Xa Medications <b>2019</b> , 933-938		1	

16	Universal Engraftment after Allogeneic Hematopoietic Cell Transplantation Using Cryopreserved CD34-Selected Grafts. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 27, 697.e1-697.e5	1
15	Process and procedural adjustments to improve CD34+ collection efficiency of hematopoietic progenitor cell collections in sickle cell disease. <i>Transfusion</i> , <b>2021</b> , 61, 2775-2781	2.9 0
14	CD34+ Enrichment and T-Cell Depletion <b>2018</b> , 51-62	
13	Rabbit Anti-Thymocyte Globulin Exposure (rATG) in CD34+ Selected Hematopoietic Cell Transplantation and Its Impact on Immune Reconstitution and Outcomes in Children and Adults. <i>Blood</i> , <b>2020</b> , 136, 30-31	2.2
12	Tie-2 Activation Is Required for Regeneration of Marrow Vasculature, Supporting Hematopoietic Reconstitution <i>Blood</i> , <b>2004</b> , 104, 1297-1297	2.2
11	Newly Discovered Polymorphism in the CD34+ Stem Cell Specific AC133-P1 Promoter Linked to Leukemias <i>Blood</i> , <b>2004</b> , 104, 2002-2002	2.2
10	Expression of Vascular Endothelial-Cadherin on Leukemic Cells Mediates Their Interaction with Vascular Endothelium <i>Blood</i> , <b>2005</b> , 106, 2761-2761	2.2
9	A High Degree of Engrafting Unit-Recipient HLA-Allele Mismatch Is Not Associated with an Increased Risk of Transplant-Related Mortality (TRM) or Inferior Progression-Free Survival (PFS) after Double Unit Cord Blood (CB) Transplantation (dCBT) in Adults with Hematologic Malignancies.	2.2
8	Double-Unit Cord Blood (CB) Transplantation with Haplo-Identical CD34+ Cells (haplo-dCBT) May Speed Neutrophil Recovery Although Successful Bridging Is Contingent on Close Haplo-Winning CB Unit HLA-Match. <i>Blood</i> , <b>2018</b> , 132, 2078-2078	2.2
7	Comparable Survival and Incidence of Toxicity for Older Adult Patients after CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , <b>2016</b> , 128, 1236-1236	2.2
6	A Comprehensive Analysis of Late Toxicities and Associated Risk Factors in Long-Term Survivors of Myeloablative Conditioned Allogeneic Hematopoietic Cell Transplantation Using Ex-Vivo CD34+ Selection-Based Graft-Versus-Host Disease Prophylaxis. <i>Blood</i> , <b>2016</b> , 128, 4621-4621	2.2
5	An Analysis of Early Toxicities, Associated Risk Factors and Survival during the First Year in Adults Undergoing Ex-Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies. <i>Blood</i> , <b>2016</b> , 128, 2194-2194	2.2
4	The Disease Risk Index Predicts Outcomes Including Relapse and Survival in CD34-Selected Allogeneic HCT for Acute Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , <b>2016</b> , 128, 3498-3498	2.2
3	Transfusion Management of Patients Receiving Antithrombotic Therapy <b>2013</b> , 343-348	
2	Human Platelet Antigens <b>2019</b> , 185-189	
1	A simplified CD34+ based preharvest prediction tool for HPC(A) collection. <i>Transfusion</i> , <b>2021</b> , 61, 1525	5-1 <u>5</u> 3 <sub>9</sub> 2